Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
ImmunoRx Pharma General Information
ImmunoRx Pharma is developing a first-in-class antibody targeting a novel pathway in chronic inflammation and autoimmunity. Its lead candidate, IRX-010, is currently in Phase 1 clinical trials for inflammatory diseases including ulcerative colitis, Crohn’s disease, and rheumatoid arthritis. The company aims to achieve proof-of-concept for this biologic therapy.
Contact Information
Primary Industry
Biotech
Corporate Office
Wilmington, Delaware
United States
United States
Drug Pipeline
No pipeline data available
Key Partnerships
TVM Capital Life Science (investor/partner)
ImmunoRx Pharma Funding
No funding data available
To view ImmunoRx Pharma's complete valuation and funding history, request access »